Email this article Laboratory parameters of hemostasis in patients with COVID-19
- Authors: Seregina E.A.1,2, Koltsova E.M.1,2, Ataullakhanov F.I.1,2, Rumyantsev A.G.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Issue: Vol 20, No 3 (2021)
- Pages: 147-155
- Section: LITERATURE REVIEW
- Submitted: 08.10.2021
- Accepted: 08.10.2021
- Published: 08.10.2021
- URL: https://hemoncim.com/jour/article/view/554
- DOI: https://doi.org/10.24287/1726-1708-2021-20-3-147-155
- ID: 554
Cite item
Full Text
Abstract
The new coronavirus infection (currently classified as COVID-19), first identified in December 2019 in Wuhan, China, has contributed to a significant increase in global mortality. Coagulopathy is a common disorder in COVID-19 patients, which develops in parallel with respiratory failure. Currently, COVID-19 continues to be a life-threatening disease and requires new developments and solutions to define preventive and curative strategies. Studies often report an abnormality in the balance of coagulation and fibrinolytic systems in COVID-19, but there is still no adequate set of laboratory tests that could provide a diagnosis of coagulopathy in COVID-19. This review analyzes current studies on the clinical manifestations of COVID-19 coagulopathy, and also analyzes the informativeness of laboratory hemostasis tests in relation to the severity of the disease and clinical outcomes.
Keywords
About the authors
E. A. Seregina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
ORCID iD: 0000-0002-7534-3863
Moscow
Russian FederationE. M. Koltsova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Author for correspondence.
Email: ekaterina_koltsova@bk.ru
ORCID iD: 0000-0003-0167-6726
Ekaterina M. Koltsova, leading researcher of the Laboratory of Translational Medicine, Deputy Director of Science–Scientific Secretary
1 Samory Mashela St., Moscow 117997
Russian FederationF. I. Ataullakhanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
ORCID iD: 0000-0003-3403-181X
Moscow
Russian FederationA. G. Rumyantsev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-1643-5960
Moscow
Russian FederationReferences
Supplementary files
